On April 28, 2025, Genprex, Inc. announced an exclusive patent license agreement with NYU Langone Health for its Reqorsa® Gene Therapy, aimed at treating mesothelioma, which could improve the company's oncology portfolio. The therapy showed promising preclinical results indicating significant tumor suppression potential.